Trial Profile
A Single Center, Randomized, Open-label, Two-arm, Parallel Design Study to Evaluate PK and Safety Profile of Multiple Ascending Oral Doses of Separately Using TG-2349 or DAG181 or TG-2349 Plus DAG181 in Healthy Chinese Volunteers
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 08 Aug 2018
Price :
$35
*
At a glance
- Drugs Furaprevir (Primary) ; Yimitasvir (Primary)
- Indications Hepatitis C
- Focus Pharmacokinetics
- Sponsors Dongguan HEC TaiGen Biopharmaceuticals
- 08 Aug 2018 New trial record